Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncipoetin alfa vs Epoetin Alfa for anemia in ESRD patients initiating dialysis
ChiCTR2600126505Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of SSS06 in anemia of renal disease and end-stage kidney disease (ESKD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Mean hemoglobin (Hb) concentration. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SSS06
03
Conditions
anemia of renal diseaseend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2600126505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126505.